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Background. Symptomatic symmetrical peripheral neuropathy (SSPN) is common in patients with HIV infection. It is also a common 
adverse event associated with both tuberculosis (TB) treatment and antiretroviral therapy (ART), particularly stavudine. While tenofovir is 
the one of recommended first-line nucleotide reverse transcriptase inhibitors (NRTIs), there is a risk of nephrotoxicity when using tenofovir 
together with the aminoglycosides needed to treat multidrug-resistant (MDR) TB. Thus, stavudine is often chosen as a treatment option 
for the HIV-infected MDR TB patient. 
Objective. To assess whether use of stavudine both before and during treatment for MDR TB increased the prevalence and incidence of SSPN. 
Method. MDR TB patients at Sizwe Tropical Disease Hospital were examined for signs of prevalent SSPN. Age, gender, HIV status, alcohol 
use, TB and HIV treatment regimens both prior to admission and current, and concomitant medications were recorded.
Results. In this cohort of 246 patients, we found that 24.4% of patients with MDR TB had SSPN at time of admission for treatment of MDR 
TB. They were more likely to be HIV-infected (odds ratio (OR) 3.21; 95% CI 1.25 - 8.21) and tended to have longer (>7 months) exposure 
to stavudine (OR 1.81; 95% CI 0.90 - 3.63). Incident SSPN occurred in 17% of patients and was associated with older age (hazard ratio (HR) 
3.00; 95% CI 1.30 - 6.89) and exposure to terizidone (HR 2.98; 95% CI 0.94 to 4.61) or, to a lesser extent, with stavudine (crude HR 1.62; 
95% CI 0.65 - 4.01) in the first 6 months of MDR TB treatment. This common adverse event emphasises the need for the development of 
less toxic drugs for the treatment of MDR TB. 
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South Africa (SA) has the fourth-highest incidence 
of multidrug-resistant (MDR) TB worldwide[1] with 
significant numbers of patient co-infected with HIV. 
At present, treatment of MDR TB is characterised by 
toxic medications, given for prolonged periods of time, 
and which have poorer efficacy than those used for drug-sensitive TB. 
One of the mainstays of MDR TB treatment, the aminoglycosides, 
can cause tubular necrosis[2] which results in functional 
nephrotoxicity.[3] For patients who are co-infected with MDR TB and 
HIV, the National Department of Health guidelines recommend they 
be started on antiretroviral therapy (ART) irrespective of their CD4+ 
count. These guidelines also suggest the use of a tenofovir-based 
first-line ART regimen, which is associated with renal dysfunction. 
Because tenofovir-related nephrotoxicity is characterised by proximal 
tubular cell dysfunction,[4] there is concern that the cumulative 
action of aminoglycosides and tenofovir may put patients at risk 
of renal failure. Zidovudine can be an alternative for tenofovir but 
the high incidence of anaemia in this population often precludes its 
use. Consequently, stavudine is often used in HIV-infected patients 
with MDR TB. However, the use of 30 mg stavudine twice daily for 6 
months during the injectable intensive phase could potentially result 
in mitochondrial toxicity and symptomatic symmetrical peripheral 
neuropathy (SSPN). We report on the prevalence and incidence of 
SSPN in a cohort of MDR TB patients admitted to an inpatient facility 
in Gauteng Province, and assess the effect of stavudine. 
Methods
Sizwe Tropical Disease Hospital is the referral facility for MDR TB 
treatment in Gauteng Province, South Africa. Patients are admitted 
here if they have resistance to isoniazid (INH) and rifampicin 
confirmed either by line probe assay or culture and drug sensitivity 
testing. All patients receive HIV counselling and testing and are 
managed according to national guidelines.[5] 
Criteria for enrolment in this prospective cohort were a confirmed 
diagnosis of MDR TB, ability and willingness to provide written 
informed consent and being 18 years or older. 
At admission, consenting patients were asked about symptoms of, 
and were examined for signs of, prevalent SSPN. The examination was 
conducted by the medical officer and included an assessment of fine-
touch, pin-prick and vibration sense. Participants were considered to 
have SSPN if they had at least one symptom (burning, pain, numbness, 
or pins and needles) or one clinical sign of neuropathy (reduced 
vibration sense or absent ankle reflexes) in both legs. The grading was 
according to the Division of AIDS Toxicity Table (see Table 1).[6] 
The results were not confirmed by nerve conduction studies, 
as the expertise and equipment needed are not available on site, 
and infection control concerns precluded transporting a patient 
to another site. Participants were assessed for incident peripheral 
neuropathy weekly for the first 4 weeks and monthly thereafter.
Age, gender, HIV status, alcohol use, TB and HIV treatment regimens 
both prior to admission and current, and concomitant medications 
were recorded. The association between potential risk factors and 
prevalent SSPN was estimated using odds ratio (OR) with 95% 
confidence intervals (CIs). Factors associated with incident SSPN 
were estimated as hazard ratios (HRs) using Cox proportional hazard 
models.
Ethical approval for the study was granted by the Human Research 
Ethics Committee of the University of the Witwatersrand.
Results
Between August 2009 and August 2011, 284 adults with MDR TB 
were admitted to Sizwe Tropical Disease Hospital, of whom 246 
(87%) consented to participate in the study. Median age was 37 years 
and 54% were female; 81% were HIV-infected with median CD4+ 
count of 200.5 cells/μl (interquartile ratio (IQR) 98.75 - 267.25). 
Few (3.3%) patients reported excessive alcohol use. At admission, 
35.7% (n=88) were already on ART. Median duration of exposure to 
stavudine was 7.4 months (IQR 2.2 - 24.5) and median exposure time 
to INH was 6 months (IQR 3 - 6). 
Sixty (24.4%) patients had SSPN at time of admission. In bivariate 
analysis, prevalent SSPN cases were more likely to be HIV-infected 
(OR 3.21; 95% CI 1.25 - 8.21) and tended to have longer (>7 months) 
exposure to stavudine (OR 1.81; 95% CI 0.90 - 3.63). However, 
they were similar to those without prevalent SSPN with regards to 
gender (OR 1.36; 95% CI 0.76 - 2.42), excessive alcohol use (OR 
1.03; 95% CI 0.23 - 4.58) ), age above 37 years (OR 1.12; 95% CI 0.60 
- 2.12), and duration of exposure to INH for >6 months (OR 0.94; 
95% CI 0.52 - 1.71) (Table 2). HIV infection remained significantly 
associated with prevalent SSPN in multivariate analysis (adjusted 
OR) 3.34; 95% CI 1.19 - 9.36). 
The 186 patients free of SSPN at baseline were followed up for 
a median of 452 days, (IQR 312 to 628 days). Thirty-one (16.7%) 
developed incident SSPN after a median of 40 days (IQR 23 - 108) 
days), corresponding to an incidence rate of 12.9 per 100 person-
years.  Incident SSPN was associated with older age (HR 3.00; 95 CI 
1.30 - 6.89) and tended to be associated with exposure to terizidone 
(HR 2.98; 95% CI  0.94 - 4.61) or stavudine (Crude HR 1.62; 95% CI 
0.65 - 4.01) in the first 6 months of MDR TB treatment. Incident SSPN 
was not associated with HIV infection (HR 1.00; 95% CI 0.36 - .91). In 
multivariate analysis, older age remained an independent risk factor for 
incident SSPN (adjusted HR 3.174; 95% CI 1.243 - 8.06).
Discussion
SSPN was common among patients admitted for MDR TB treatment, 
with a prevalence of 24.4% and incidence rate of 12 per 100 person- 
years.
We found that HIV infection was independently associated with 
prevalent SSPN, but was not associated with incident SSPN. HIV-
Table 1. Division of AIDS Toxicity Table[6]
Grade 1: Mild Neurosensory alteration (including paraesthesia and painful neuropathy). Asymptomatic with sensory 
alteration on exam or minimal paraesthesia causing no or minimal interference with usual social and functional 
activities.
Grade 2: Moderate Sensory alteration or paraesthesia causing greater than minimal interference with usual social and functional 
activities.
Grade 3: Severe Sensory alteration or paraesthesia causing inability to perform usual social and functional activities.
Grade 4: Potentially 
life-threatening
Disabling sensory alteration or paraesthesia causing inability to perform basic self-care functions.
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associated SSPN has been associated with low CD4+ count and a 
high viral load, suggesting a possible reduction in risk when ART 
is initiated early.[7] 
Duration of exposure to INH prior to admission was not associated 
with increased prevalence of SSPN in our cohort. However, the 
frequency of INH-associated SSPN has been shown to be mediated 
by HIV infection, with HIV-infected TB patients having a four-
fold higher risk.[8] INH-associated SSPN is also dose-related, with 
2 - 12% of patients receiving 3 - 5 mg/kg/day INH developing SSPN, 
compared with 44% of those receiving 16 - 24 mg/kg/day.[9] We could 
not assess the effect of INH dosage in this cohort as only 4 patients 
received a high dose of INH for treatment of MDR TB. 
Exposure to stavudine is a well-documented risk factor for 
SSPN[10,11] and tended to increase the risk of SSPN in our study 
cohort. However, compared with the risk of renal disease, this was not 
considered to be sufficient reason not to use stavudine. 
Terizidone may further increase the risk of INH-associated SSPN 
as it inhibits pyridoxine activity.[9] Terizidone-associated nervous 
system toxicities have been reported, usually within the first 2 weeks, 
but rarely include SSPN. In our cohort, exposure to terizidone tended 
to increase the risk of incident SSPN, but this was not statistically 
significant. 
Study limitations
Very ill and confused patients could not provide consent and were 
excluded, which may have led to an underestimation of the rate of 
SSPN. The diagnosis of SSPN was based on clinical examination 
only, as we did not have the capacity to perform electrophysiological 
studies. 
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Table 2. Risk factor for incident and prevalent SSPN
Crude OR (95% CI) Adjusted OR (95% CI) Crude HR (95% CI) Adjusted HR (95% CI)
Prevalent SSPN
 HIV status (negative v. invected) 3.21 (1.25 - 8.22) 3.34 (1.19 – 9.36)
 Gender (female v. male) 1.36 (0.76 - 2.42) 1.40 (0.75 – 2.61)
 Age (≤37 years v. >37 years) 1.13 (0.60 - 2.12) 1.26 (0.24 – 1.72)
 Duration of treatment with stavudine 
(≤7 months v. >7 months)
1.81 (0.90 - 3.67) 1.50 (0.72 – 3.11)
 Duration of treatment with isoniazid 
(≤6 months v. >6 months)
0.94 (0.52 - 1.71) 1.41 (0.61 – 2.14)
 Excessive alcohol use  
(alcohol consumption >3 times/week v. 
<3 times/week)
1.03 (0.23 - 4.58) 1.17 (0.18 – 5.89)
Incident SSPN
 HIV status (negative v. invected) 1.00 (0.35 - 2.91) 1.12 (0.36 - 3.50)
 Stavudine in first 6 months (no v. yes) 1.62 (0.65 - 4.01) 2.43 (0.84 - 7.03)
 TZD in the first 6 months (no v. yes) 2.08 (4.61 - 0.94) 1.76 (0.76 - 4.08)
 Age (≤37 years v. >37 years) 3.00 (1.30 - 6.89) 3.17 (1.243 - 8.06)
 Gender (female v. male) 1.65 (0.73 - 3.74) 1.46 (0.62 - 3.43)
SSPN = symptomatic symmetrical peripheral neuropathy; OR = odds ratio; CI = confidence interval; HR = hazard ratio; TZD = terizidone.
